New two-year data from the JEWELFISH study evaluating Evrysdi (risdiplam)
Roche announces new two-year data from the JEWELFISH study evaluating Evrysdi (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at the time of enrolment. The data will be first presented at the 27th World Muscle Society (WMS) congress, 11-15 October 2022.
It will be also announced during the Roche PAG Scientific Meeting taking place during our 3rd Scientific Congress on Spinal Muscular Atrophy in Barcelona on Saturday, 22 October at 4 pm.
JEWELFISH is a safety trial evaluating Evrysdi in people previously treated with other approved or investigational SMA-targeting therapies, including nusinersen (Spinraza) or onasemnogene abeparvovec (Zolgensma).